Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 15/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.50 |
| ▸ | CDK2 | P24941 | 2/20 | 0.49 |
| ▸ | CDK16 | Q00536 | 1/20 | 0.49 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.49 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.48 |
| ▸ | FLT3 | P36888 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17438030 | 0.79 | NR4A2 (0.58) | — | |
| SCHEMBL17447387 | 0.78 | ALDH1A1 (0.54) | — | |
| SCHEMBL4794844 | 0.75 | KDM4E (0.63) | GSK3BSMN1; SMN2ROCK1CDK2FLT3 | |
| SCHEMBL17447381 | 0.74 | MAPT (0.56) | ROCK1ROCK2 | |
| SCHEMBL15210880 | 0.74 | GSK3B (0.78) | GSK3BCDK2CDK16DYRK1A | |
| SCHEMBL929332 | 0.74 | PRKAG1 (0.79) | GSK3BROCK1CDK2FLT3 | |
| SCHEMBL17324787 | 0.74 | PRKAG1 (0.62) | GSK3BSMN1; SMN2ROCK1CDK2DYRK1A | |
| SCHEMBL18910657 | 0.73 | TUBB1 (0.50) | — | |
| Hydrochloric Acid SCHEMBL15210531 | 0.73 | GSK3B (0.76) | GSK3BCDK2CDK16DYRK1A | |
| SCHEMBL17447428 | 0.73 | PKM (0.66) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10273208-B2 | Screening methods for the binding affinity of chemical entities to biological molecules and NEDD4-1 inhibitors identified by the screening methods | NORTHWESTERN UNIVERSITY (US) | 2019-04-30 | — | — | US | disclosed |
| US-20170152228-A1 | SCREENING METHODS FOR THE BINDING AFFINITY OF CHEMICAL ENTITIES TO BIOLOGICAL MOLECULES AND NEDD4-1 INHIBITORS IDENTIFIED BY THE SCREENING METHODS | NORTHWESTERN UNIVERSITY (US) | 2017-06-01 | — | — | US | disclosed |
| US-9586890-B2 | Screening methods for the binding affinity of chemical entities to biological molecules and NEDD4-1 inhibitors identified by the screening methods | NORTHWESTERN UNIVERSITY (US) | 2017-03-07 | — | — | US | disclosed |
| US-20160016893-A1 | SCREENING METHODS FOR THE BINDING AFFINITY OF CHEMICAL ENTITIES TO BIOLOGICAL MOLECULES AND NEDD4-1 INHIBITORS IDENTIFIED BY THE SCREENING METHODS | NORTHWESTERN UNIVERSITY (US) | 2016-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170152228-A1 | SCREENING METHODS FOR THE BINDING AFFINITY OF CHEMICAL ENTITIES TO BIOLOGICAL MOLECULES AND NEDD4-1 INHIBITORS IDENTIFIED BY THE SCREENING METHODS | NEDD4, STUB1, CUL1 | GSK3B 1843/4885SMN1; SMN2 4028/4885ROCK1 1348/4885 |
| US-20160016893-A1 | SCREENING METHODS FOR THE BINDING AFFINITY OF CHEMICAL ENTITIES TO BIOLOGICAL MOLECULES AND NEDD4-1 INHIBITORS IDENTIFIED BY THE SCREENING METHODS | NEDD4, STUB1, UBQLN1 | GSK3B 555/4885SMN1; SMN2 2107/4885ROCK1 1815/4885 |
| US-10273208-B2 | Screening methods for the binding affinity of chemical entities to biological molecules and NEDD4-1 inhibitors identified by the screening methods | NEDD4, STUB1, CUL1 | GSK3B 1843/4885SMN1; SMN2 4028/4885ROCK1 1348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.